Methyl-CCNU, doxorubicin, and cis-diaminedichloroplatinum II in the management of recurrent and metastatic squamous carcinoma of the cervix

Publisher Website
Google Scholar
Abstract
Twenty-three patients with recurrent unresectable carcinoma of the cervix or distant metastasis at initial presentation were treated with methyl-CCNU (175 mg/m2) and doxorubicin (45 mg/m2) on day 1 and Cis-diaminedichloroplatinum II (90 mg/m2) on day 22 of a 42-day treatment cycle. Twenty-two patients had squamous carcinoma and 1 had adenosquamous carcinoma. There were two complete responses (CR), five partial responses (PR) (>50% tumor reduction, >3-month duration), four patients with stable disease (3-month duration), and 12 patients who had tumor progression. One CR has been maintained > 28 months, and the other >8 months. Total CR and PR was 7 of 23 (30.4%). Three responses occurred among 15 patients (20%) who had cancer primarily confined to the pelvis, while 4 of 8 patients (50%) with distant metastasis responded. During the initial 2 cycles of chemotherapy, 12 patients had myelosuppression, defined as a leukocytes 3, granulocytes 3, or platelets 3. There were no treatment-related deaths.